Piramal Pharma Posts Strong Q1 FY27 Results

Revenue from operations ₹2,270 Crore, Net Profit (PAT) (₹69) Crore

Reader Takeaway: Robust revenue growth and significant EBITDA margin expansion driven by operational efficiency, balanced by watchful customer decision timelines.

What just happened

Piramal Pharma Ltd. has reported its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27). The company achieved a consolidated revenue from operations of ₹2,270 crore, a 17% increase compared to ₹1,934 crore in the same period last year.

EBITDA for the quarter rose significantly by 72% to ₹285 crore, up from ₹165 crore in Q1 FY26. This led to an expansion of EBITDA margin by 400 basis points, reaching 12.5% from 8.5% a year ago.

The company reported a Net Profit (PAT) of (₹69) crore for Q1 FY27, an improvement of 15% from a loss of (₹82) crore in Q1 FY26.

Why this matters

This performance indicates Piramal Pharma's ability to grow its top line across all key segments while also improving profitability. The substantial increase in EBITDA and margin expansion suggest effective cost management and operational leverage. The reduced net loss also points towards a positive financial trajectory.

The backstory

In the previous financial year, Piramal Pharma had focused on integrating its businesses and driving efficiencies. The company has been strategically advancing its Antibody-Drug Conjugate (ADC) platform and expanding its manufacturing capabilities.

What changes now

The strong Q1 FY27 performance sets a positive tone for the fiscal year. The company's continued investment in its ADC platform and expansion of sterile injectables capacity are expected to be key growth drivers. Integration of products like Kenalog is also slated to commence, contributing from Q2 FY27.

Risks to watch

Management highlighted that customer decision-making timelines in the Contract Development and Manufacturing Organization (CDMO) business remain prolonged, which could impact revenue conversion speed.

Persistent input-cost inflation, particularly for raw materials, remains a concern that requires continuous pricing and optimization discipline to maintain margins.

Peer comparison

While specific peer financial data for Q1 FY27 is not yet widely available, Piramal Pharma's reported growth and margin expansion across its segments, particularly in CDMO and Complex Hospital Generics, appear robust. The company competes in a sector with players like Syngene International, Laurus Labs, and Divi's Laboratories in the CDMO space.

Context metrics (time-bound)

• Consolidated Revenue (Q1 FY27): ₹2,270 Crore (up 17% YoY)
• EBITDA (Q1 FY27): ₹285 Crore (up 72% YoY)
• EBITDA Margin (Q1 FY27): 12.5% (up 400 bps YoY)
• Net Profit (PAT) (Q1 FY27): (₹69) Crore (improved 15% YoY)
• CDMO Revenue (Q1 FY27): ₹1,187 Crore (up 19% YoY)
• CHG Revenue (Q1 FY27): ₹743 Crore (up 17% YoY)
• PCH Revenue (Q1 FY27): ₹347 Crore (up 15% YoY)

What to track next

Investors will be watching the company's ability to manage inflationary pressures and the conversion of CDMO business opportunities into firm orders. Progress on the ADC platform and the integration of new product lines will also be key areas to monitor.

US FDA inspection outcomes and their impact on operations are also critical for the company's manufacturing-centric businesses.